Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kissei-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:18303:1" rel="noopener">Kissei Pharmaceutical (4547 JP)</a> reported 14% YoY jump in revenue during 9MFY25 driven by Beova and Tavneos amidst price revision pressures and generic competition.</li>
<li>The company has reiterated FY25 guidance of revenue rising 14% YoY, with major drugs witnessing growth.</li>
<li>Main trigger point happens to be the in-licensing deal and the sub-licensing agreements the company has signed with various players giving an opportunity to expand its market in near future.</li>
</ul>



Kissei Pharmaceutical (4547 JP) reported 14% YoY jump in revenue during 9MFY25 driven by Beova and Tavneos amidst price revision pressures and generic competition.
The company has reiterated FY25 guidance of revenue rising 14% YoY, with major drugs witnessing growth.
Main trigger point happens to be the in-licensing deal and the sub-licensing agreements the company has signed with various players giving an opportunity to expand its market in near future.


Kissei Pharmaceutical (4547 JP): FY25 Looks Stable; Recent Licensing Deals Key To Near Term Growth

United States

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rigel Pharmaceuticals (RIGL US)

Kissei Pharmaceutical (4547 JP): FY25 Looks Stable; Recent Licensing Deals Key To Near Term Growth

Kissei Pharmaceutical sees 14% revenue growth in 9MFY25 driven by key drugs despite price pressures and generics, maintains FY25 guidance, with...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Kissei Pharmaceutical (4547 JP): FY25 Looks Stable; Recent Licensing Deals Key To Near Term Growth

​Kissei Pharmaceutical sees 14% revenue growth in 9MFY25 driven by key drugs despite price pressures and generics, maintains FY25 guidance, with...

Tina Banerjee

Kissei Pharmaceutical sees 14% revenue growth in 9MFY25 driven by key drugs despite price pressures and generics, maintains FY25 guidance, with...